Song Peng, Cui Yong
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Zhongguo Fei Ai Za Zhi. 2024 May 20;27(5):383-390. doi: 10.3779/j.issn.1009-3419.2024.106.11.
Lung cancer is still the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for about 80%. Approximately 30% of all patients with NSCLC have resectable early and middle stage disease at the time of diagnosis. Recently, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have made a major breakthrough in the adjuvant targeted therapy of EGFR-mutated resectable NSCLC, and are recommended by the guidelines for clinical use. In this review, we summarize the clinical research progress of perioperative adjuvant targeted therapy for EGFR-mutated resectable NSCLC, and discuss the key issues in the clinical researches. .
肺癌仍是全球癌症死亡的主要原因。非小细胞肺癌（NSCLC）是肺癌的主要病理类型，约占80%。所有NSCLC患者中，约30%在诊断时患有可切除的早中期疾病。近年来，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）在EGFR突变的可切除NSCLC辅助靶向治疗方面取得了重大突破，并被指南推荐用于临床。在本综述中，我们总结了EGFR突变的可切除NSCLC围手术期辅助靶向治疗的临床研究进展，并讨论了临床研究中的关键问题。
